Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Overview

NASDAQ:APLS - US03753U1060 - Common Stock

27.52 USD
-0.45 (-1.61%)
Last: 8/25/2025, 8:04:42 PM
27.52 USD
0 (0%)
After Hours: 8/25/2025, 8:04:42 PM

APLS Key Statistics, Chart & Performance

Key Statistics
52 Week High41.94
52 Week Low16.1
Market Cap3.48B
Shares126.29M
Float107.20M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.82
PEN/A
Fwd PEN/A
Earnings (Next)11-03 2025-11-03/bmo
IPO11-09 2017-11-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


APLS short term performance overview.The bars show the price performance of APLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

APLS long term performance overview.The bars show the price performance of APLS in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of APLS is 27.52 USD. In the past month the price increased by 46.77%. In the past year, price decreased by -29.25%.

APELLIS PHARMACEUTICALS INC / APLS Daily stock chart

APLS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.6 366.65B
AMGN AMGEN INC 13.23 155.30B
GILD GILEAD SCIENCES INC 14.75 141.64B
VRTX VERTEX PHARMACEUTICALS INC 22.96 99.72B
REGN REGENERON PHARMACEUTICALS 12.54 60.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.15B
ARGX ARGENX SE - ADR 73.07 41.45B
ONC BEONE MEDICINES LTD-ADR 6.23 36.69B
INSM INSMED INC N/A 27.12B
BNTX BIONTECH SE-ADR N/A 25.26B
NTRA NATERA INC N/A 22.30B
BIIB BIOGEN INC 8.52 19.99B

About APLS

Company Profile

APLS logo image Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Company Info

APELLIS PHARMACEUTICALS INC

100 Fifth Avenue

Waltham MASSACHUSETTS 02451 US

CEO: Cedric Francois

Employees: 705

APLS Company Website

APLS Investor Relations

Phone: 16179775700

APELLIS PHARMACEUTICALS INC / APLS FAQ

What is the stock price of APELLIS PHARMACEUTICALS INC today?

The current stock price of APLS is 27.52 USD. The price decreased by -1.61% in the last trading session.


What is the ticker symbol for APELLIS PHARMACEUTICALS INC stock?

The exchange symbol of APELLIS PHARMACEUTICALS INC is APLS and it is listed on the Nasdaq exchange.


On which exchange is APLS stock listed?

APLS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for APELLIS PHARMACEUTICALS INC stock?

28 analysts have analysed APLS and the average price target is 38.53 USD. This implies a price increase of 40.02% is expected in the next year compared to the current price of 27.52. Check the APELLIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is APELLIS PHARMACEUTICALS INC worth?

APELLIS PHARMACEUTICALS INC (APLS) has a market capitalization of 3.48B USD. This makes APLS a Mid Cap stock.


How many employees does APELLIS PHARMACEUTICALS INC have?

APELLIS PHARMACEUTICALS INC (APLS) currently has 705 employees.


What are the support and resistance levels for APELLIS PHARMACEUTICALS INC (APLS) stock?

APELLIS PHARMACEUTICALS INC (APLS) has a support level at 26.96 and a resistance level at 27.97. Check the full technical report for a detailed analysis of APLS support and resistance levels.


Is APELLIS PHARMACEUTICALS INC (APLS) expected to grow?

The Revenue of APELLIS PHARMACEUTICALS INC (APLS) is expected to grow by 20.45% in the next year. Check the estimates tab for more information on the APLS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy APELLIS PHARMACEUTICALS INC (APLS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APELLIS PHARMACEUTICALS INC (APLS) stock pay dividends?

APLS does not pay a dividend.


When does APELLIS PHARMACEUTICALS INC (APLS) report earnings?

APELLIS PHARMACEUTICALS INC (APLS) will report earnings on 2025-11-03, before the market open.


What is the Price/Earnings (PE) ratio of APELLIS PHARMACEUTICALS INC (APLS)?

APELLIS PHARMACEUTICALS INC (APLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.82).


What is the Short Interest ratio of APELLIS PHARMACEUTICALS INC (APLS) stock?

The outstanding short interest for APELLIS PHARMACEUTICALS INC (APLS) is 20.72% of its float. Check the ownership tab for more information on the APLS short interest.


APLS Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to APLS. When comparing the yearly performance of all stocks, APLS is one of the better performing stocks in the market, outperforming 77.96% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

APLS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to APLS. APLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APLS Financial Highlights

Over the last trailing twelve months APLS reported a non-GAAP Earnings per Share(EPS) of -1.82. The EPS increased by 30% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -27.78%
ROE -145.98%
Debt/Equity 2.9
Chartmill High Growth Momentum
EPS Q2Q%-17.86%
Sales Q2Q%-10.61%
EPS 1Y (TTM)30%
Revenue 1Y (TTM)20.02%

APLS Forecast & Estimates

28 analysts have analysed APLS and the average price target is 38.53 USD. This implies a price increase of 40.02% is expected in the next year compared to the current price of 27.52.

For the next year, analysts expect an EPS growth of 45.53% and a revenue growth 20.45% for APLS


Analysts
Analysts77.86
Price Target38.53 (40.01%)
EPS Next Y45.53%
Revenue Next Year20.45%

APLS Ownership

Ownership
Inst Owners102.53%
Ins Owners3.74%
Short Float %20.72%
Short Ratio9.16